UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced evidence that its SGLT2 inhibitor, Forxiga (dapagliflozin), provides significant clinical benefits in patients with heart failure (HF) with preserved ejection fraction (pEF) and chronic obstructive pulmonary disease (COPD). This announcement highlights the potential of Forxiga in treating these conditions and underscores its role in managing related comorbidities.
Data Presentation at Cardiology Conference
The results, which are further supported by findings on the connection between heart failure and kidney disease, are slated to be published at a forthcoming cardiology conference later this month. These findings are expected to contribute to the ongoing dialogue on the management of heart failure and its associated complications.
Phase I Data for AZD5462
In addition to the Forxiga data, the conference will also feature Phase I data for AstraZeneca’s selective relaxin family peptide receptor 1 (RXFP1) agonist, AZD5462. This drug is designed to mimic the effects of the pregnancy hormone relaxin on systemic haemodynamics and kidney function, offering a novel approach to treating cardiovascular and renal conditions.-Fineline Info & Tech
